부산대학교 도서관

To study the human teratogenic potential of two acetylsalicylic acid (ASA) drugs ASA-100 mg and ASA-500 mg. Pair analysis of cases with congenital abnormalities and matched healthy controls. The large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980–1996. 38,151 pregnant women who had newborn infants without any defects (population control group); 22,865 case pregnant women who had newborns or fetuses with congenital abnormalities and 812 patient controls who had offspring with Down's syndrome. In the case group 1073 (4.7%) and in the population control group 1505 (4.0%), while in the patient control group 52 (6.4%) of the pregnant women were treated with ASA. The ASA-500 was the major group because 1050 (4.6%) case, 1471 (3.9%) population control and 50 (6.2%) patient control pregnant women had this treatment. The case-control pair analysis did not indicate a higher rate of any ASA treatments during 2–3 months of gestation, i.e. in the critical period for most major congenital abnormalities. Thus all three of our analyses, i.e. — (1) in matched case-control pairs; (2) the comparison of medically recorded ASA use in the total control group and subjects with congenital abnormalities; (3) the comparison of the occurrence of ASA treatment between the patient control group and subjects with congenital abnormalities. Treatment with ASA drugs studied during pregnancy did not indicate a higher teratogenic risk to the fetus. Copyright © 2000 John Wiley & Sons, Ltd.